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Bonediseaseinpatients withjuvenileidiopathicarthritis(JIA)isassociatedwithfocal(jointerosionandjuxtaarticularosteopenia)
and systemic bone loss (generalized osteopenia or reduction of bone mass density). Pathophysiology of bone loss is multifactorial
and involves particularly proinﬂammatory cytokines and deleterious eﬀects of glucocorticoid therapy. Clinical studies in patients
withJIAindicate excessive activationofosteoclastogenesisandreduction ofboneformation.Reduction ofphysicalactivity, muscle
atrophy caused by high disease activity, and compulsory restriction in movements are also associated with bone loss. In patients
with JIA, the disease can be complicated by growth cartilage involvement and systemic or local growth retardation. In the absence
of preventive measures, fragility fractures can occur even at an early age.
1.Introduction
Juvenile idiopathic arthritis (JIA) is a systemic autoimmune
chronic inﬂammatory joint disease beginning until 16 years
of age. JIA is the most frequent rheumatic systemic disease
in the childhood. In the industrial countries, the incidence
of JIA is 5–18 and prevalence of JIA is 30–150/100000
childrenuntil 16 years old.In the Czech Republic,the annual
incidence of JIA is 13/100 000 and prevalence of JIA is
140/100000 children until 16 years old [1]. The initial cause
of the chronic inﬂammatory processes targeting the synovial
lining of joints is not known. Many of the proinﬂammatory
factors stimulate the diﬀerentiation of osteoclasts from the
hematopoieticprecursor.Generalizedbonelossofbonemass
is a common feature in JIA.
2.LowBone Massand Increased
RiskofFracture
During childhood and adolescence in patients with JIA,
when the peak of bone mass is attained in the healthy
people, the accrual of bone mass is suppressed through
direct andindirect mechanisms, namelybytheinﬂammatory
disease, by drug therapy and immobilization [2, 3]. In JIA,
both synovial-derived and soluble cytokines are involved.
Osteopenia or osteoporosis occurs in all of the JIA forms,
most typically in systemic and polyarticular forms ofdisease.
The low bone mass is associated with the high activity of
the disease and with the number of involved joints in JIA
patients [4–9], also with the reduction of bone formation
[4, 6]. Reduced bone mineral density (BMD) is observed at
all sites of the skeleton in the children and adolescents with
JIA and also in adults with JIA. In the cross-sectional study,
the low BMD in lumber spine and hip was found in 40–52%
adultpatientswithJIA[10].However,eventhefullremission
of the disease in young adults is not able to completely
normalize BMD at all skeletal sites. In 229 young adults with
a past history of JIA, persistently low BMD was observed at
the femoral neck and on total body [11]. In another study,
41% of adults with a history of JIA had osteopenia [12].
Therapy with glucocorticoidscan prevent the acquisition
of an optimal peak bone mass in young patients. The lower2 Journal of Osteoporosis
peak of bone mass is associated with the increased risk of
osteoporosis and the increased risk of fracture in the adult
age [13–15].
Drug therapy with glucocorticoids may increase the risk
ofdevelopingosteopeniaandosteoporosis.Vertebralcollapse
is more common in children receiving a cumulative dose of
at least 5g of prednisone equivalents, prolonged periods of
bed rest, and with low BMD and low serum concentrations
of 25-hydroxyvitamin D [13, 16]. In a study in 103 patients
with JIA, 23% had at least one fracture in the presence of
growth failure, articular erosions and high cumulative dose
ofglucocorticoids;56% of these fractures were vertebral [17]
(Figure 1).
3.FracturesandLowLeanMass
The increased risk of fracture has been proven especially in
patients with erosive arthritis, growth retardation and high
cumulative dose of glucocorticoids [2, 3].
Myopathy caused by the autoimmune inﬂammation is
one of reasons of the low lean mass in patients with JIA.
Proinﬂammatory cytokines (especially TNF-α)s t i m u l a t e
protein degradation, inhibit myocyte diﬀerentiation, and
cause myocyte apoptosis [18, 19], as demonstrated by the
muscle biopsies [20]. Glucocorticoid myopathy can also
induce a low lean mass [21]. Patients with JIA are less physi-
cally active than healthy population, their physical condition
is impaired, and risk of fracture is increased [22, 23].
In patients with JIA, there is an important relationship
between risk of fracture, bone mineral density and quantity
of lean mass. The lean mass corelates with BMD at the
various skeletal sites. Bone status in children with JIA (and
also in healthy children) markedly depends on the muscle
force aﬀecting the skeleton [4, 18]. Reduction of whole body
lean mass and higher accrual of fat mass was established
at the early phase of the disease [8]. The increased risk of
forearm fracture was demonstrated also in healthy children
and adolescents with low whole body lean mass and high fat
mass [24]. BMD at the cortical and trabecular bone of the
forearm and bone and lean muscle geometry was measured
in 57 children with JIA using the peripheral quantitative
computed tomography (QCT) [18]. Patients with JIA had
signiﬁcantly reduced cross-sectional area of the lean muscle
mass (CSA). This reduction notably corelated with lean
mucle force and bone geometry abnormalities and with
signiﬁcant reduction of the cortical bone thickness. All of
these can be associated with increased risk of fracture. The
peripheral QCT was also used to demonstrate a reduced calf
lean muscle mass and tibial trabecular BMD and cortical
thickness in patients with JIA [25].
4.GrowthRetardation
The important diﬀerence between JIA and rheumatoid
arthritis in adults lies in growth retardation of children
with JIA, deceleration of growth rate, low stature in adult
age and local growth retardation at sites of joints involved
in arthritis [2, 3]. A signiﬁcantly low stature (the ﬁnal
height below −2 standard deviation, SD) was demonstrated
(a) (b)
Figure 1:Multiple compressivevertebral fractures andrib fractures
in a 22-year-old women diagnosed with JIA at 3years of age. Bone
densitometry (DXA, GE Prodigy): total femurBMDof0,453g/cm2,
T-score −4,5; femur neck BMD of 0,536g/cm2,T - s c o r e−4,2.
in 11% of children with JIA, and in 41% children with
systemic form of disease [26]. Sources of growth retardation
in JIA are multifactorial; chronic inﬂammation and long-
term glucocorticoid treatment are the most relevant. The
linear growth can be improved with remission of the disease.
The growth hormone (GH) and insulin-like growth fac-
tor I (IGF-I) are the most important regulators of postnatal
growth. In children with JIA and serious growth retardation,
the normal pulsative secretion of growth hormone, but low
levels of IGF-I were described (resistance to growth hor-
mone). Proinﬂammatory cytokines inﬂuence linear growth
of children by their systemic eﬀects and by local eﬀects on
growth cartilage of long bones [26]. Increased production of
interleukin6(IL-6)andinterleukin1beta(IL-1β) accelerates
degradation of insulin-like growth factor I binding protein 3
(IGFBP-3) resulting in reduction of IGF-I levels and growth
retardation. Chondrocyte apoptosis induced by the tumor
necrosisfactorα(TNFα)throughthemediumFas-associated
death domain (FADD) acts the important part in growth
abnormalities [26]. Growth retardation caused by chronic
inﬂammation and glucocorticoidtreatment can be positively
inﬂuenced by growth hormone treatment [27].
5.Biochemical Markersof Bone Turnover
Studies of bone formation and bone resorption markers
are not unambiguous; however, most studies indicated
prevalence of bone resorption over bone formation [5],Journal of Osteoporosis 3
the others conversely indicate reduction of the bone for-
mation [4, 6, 28]. Decreased bone formation in the course
of adolescent growth spurt obstructs achievement of peak
of bone mass and increase risk of fracture in the adult age
[4, 13, 14]. Successful treatment of the disease is associated
with elevation of bone formation markers [6].
In prepubertal children with active JIA, prevalence of
bone resorption markers over reduced markers of bone
formation corelated with laboratory indices of disease activ-
ity, namely in children with polyarticular phase of JIA [4,
6, 28, 29]. Except for the high disease activity, reduced
concentrations of bone turnover markers and low BMD
were found in patients with joint destruction and longer
disease duration [29]. According to Pereira et al., bone
formation in patients with JIA was suppressed from early to
middle puberty, while at older patients with JIA, the main
factor of bone loss was the elevation of bone resorption
[30]. Thus, similarly to adults with rheumatoid arthritis,
the proinﬂammatory cytokines (TNF-α, IL-1) produced
by synovial membrane are responsible for excessive bone
resorption also in adult patients with JIA [31].
6.Cellularand MolecularMechanisms of
Bone RemodelinginPatientswithJIA
6.1. Inﬂuence of Proinﬂammatory Cytokines on Bone Remod-
eling. Proinﬂammatory cytokines, such as tumor necrosis
factor α (TNFα), interleukin 1 (IL-1), interleukin 6 (IL-6)
a interleukin 17 (IL-17), present in arthritic joint can cause
an excessive osteoclastogenesis [32–35]. TNFα signiﬁcantly
elevates bone resorption [36] and attenuates osteoblasto-
genesis and bone formation [37–40]. IL-1 also accelerates
osteoclast maturation [41]. In patients with rheumatoid
arthritis, treatment with TNFα antibodies demonstrably
reduces joint erosions [32]. IL-17, which is produced by
T-lymfocytes [34, 42, 43] induces osteoclast diﬀerentiation
by increasing expression of RANKL and RANK. On the
contrary, IL-17 suppresses expression of osteoprotegerin in
osteoblasts resulting in prevalence of bone resorption over
bone formation and bone loss [6, 34, 44–46].
6.2. RANKL/RANK/OPG Triad in Patients with JIA. Recep-
tor activator nuclear factor kappa B (RANK) and its ligand
(´ RANKL) have essential importance for osteoclastogenesis
and osteoclast function [47–50]. Osteoprotegerin (OPG) is a
soluble decoy receptor for RANKL produced by osteoblasts.
OPG binding to RANKL prevents RANKL activation of
RANK and thus activation of the osteoclastogenesis [48,
51]. High RANKL/OPG ratio results in prevalence of bone
resorption over bone formation [52].
Increased production of RANKL in synovial ﬂuid and
increased concentrations ofR A N K Li ns e r u ma r ef o u n d
in adults with rheumatoid arthritis [53]. An increased
RANKL/OPG ratio was observed in children with juvenile
dermatomyositis, and in patients with juvenile idiopathic
arthritis [54, 55]. In the later study in patients with JIA,
increased serum OPG concentrations were not suﬃcient to
compensate for increased levels of RANKL [54, 55]. Serum
concentrations of RANKL were increased in all the forms of
JIA [55]. An increased RANKL/OPG ratio was also found in
a subset of 30 girls with polyarticular course of highly active
JIA and joint erosions [56], and in synovia in patients with
polyarticular and enthesitis-related forms of JIA [57].
6.3. Wingless Proteins (Wnt) Signalling Pathway. The extent
of the bone involvement in the rheumatic inﬂammatory
processes depended on age and bone maturity [34]. In
children with JIA, decreased osteoblastic formation and
function may contribute to the bone loss [30, 34, 58, 59].
With this respect, the proinﬂammatory cytokines (especially
TNFα), stimulate production of inhibitors of the Wnt pro-
teins signalling pathway, especially sclerostin and Dickkopf1
(DKK-1) and consequently inhibit osteoblast diﬀerentiation
[60–63]( Figure 1).
The Wnt proteins are large family of factors that bind
to cell-surface receptors of the Frizzled family, causing the
receptors to activate Dishevelled family proteins and ulti-
mately resulting in a change in the amount of β-catenin that
reaches the nucleus and interacts with T-cell factor/lymhoid
enhancer factor (TCF/LEF) family transcription factors to
promotespeciﬁcgeneexpression[64].Decreasedproduction
of DKK-1, an inhibitor of the Wnt signaling pathway, is
associated with reverse of osteoresorptive pattern in mouse
model of rheumatoid arthritis to pattern of osteoarthritis
with increased bone formation and osteophyte formation
[61]. The DKK-1 blockade is associated with stimulation
of OPG production by osteoblasts and consequent decrease
in bone resorption [61, 64]. The importance of Wnt
proteins for susceptibility to JIA was conﬁrmed in the study
of Wnt-1 inducible signaling pathway protein 3 (WISP3)
polymorphism [65].
6.4. Matrix Metalloproteinases and Their Inhibitors in Patients
withJIA. Matrixmetalloproteinases (MMPs)areresponsible
for cartilage destruction and periarticular bone erosions in
juvenile idiopathic arthritis [21, 55, 66–68]. MMP1/tissue
inhibitor of metalloproteinases 1 (TIMP1) and MMP3/
TIMP1 ratios are signiﬁcantly higher in all the forms of JIA
in comparison to healthy controls. These ratios signiﬁcantly
correlate with disease activity and could be eﬃcacious
biomarkers for monitoring of disease development [55].
7. Effectsof Glucocorticoids,and Disease-
Modifying AntirheumaticDrugs(DMARDs)
In children, a negative correlation between bone mass and
cumulative dose of glucocorticoids was found [69–71].
During the childhood and adolescence, glucocorticoids can
impair physiological process of bone mass accumulation and
can cause deterioration of peak of bone mass resulting in
increased risk of fracture in future life.
Methotrexate, which is the most frequent DMARDs in
children, can cause osteopenia in children patients with
malignancies, but low-dose methotrexate used in inﬂam-
matory diseases did not inﬂuence negatively the bone mass
[72, 73].4 Journal of Osteoporosis
8.TherapeuticOptionsto Improve Bone
StatusinJIA
8.1. TNFα Antibodies Treatments. Biological treatment with
inﬂiximab and etanercept in children with JIA is associated
with decrease in disease activity [74–76]. The positive
inﬂuence of treatment with TNFα antibodies was also
documented upon the skeleton. Simonini was the ﬁrst to
demostrate increased bone mass after 1-year etanercept
treatment in children with JIA; reduction of bone loss was
associated with therapeutic response with decreased disease
activity [75]. Etanercept also improves the linear growth in
children with JIA [76].
8.2. Antiresorption Treatments. Aminobisphosphonates rep-
resent an eﬀective option in patients with documented
prevalence of bone resorption over bone formation [77].
In JIA, calcium and vitamin D, calcitonin, and aminobis-
phosphonates have been studied [78–80]. However, studies
treated small numbers of patients with diﬀerent charac-
teristics of JIA, and controlled studies on both preventive
strategies and treatment in augmenting bone mass and
reducing the fracture risk are still lacking.
8.3. Bone Anabolic Treatments. Growth hormone was eﬀec-
tive in stimulating collagen production and improving
liner growth in JIA [81–83]. However, long-term controlled
studies are needed to determine impact on bone mass and
boneturnoverandtherisksofgrowthhormonetherapy[84].
In adult patients with closed linear growth and severe
osteoporosis, an intermittent administration of PTH 1–34
(teriparatide) or PTH 1–84 represents an eﬀective option to
restore bone structure that has previously been lost [85].
9.Conclusion
Well-timed and eﬃcient treatment of JIA in children and
adolescents can improve bone status. However, patients who
suﬀered from JIA during childhood and adolescence may
attain decreased bone mass and have an increased risk of
fragilityfractures. Itis important toidentify thesubjects with
an increased risk of fracture as early as possible. In adult
patients with closed linear growth, it is necessary not only to
reduceboneresorption,butalsotosupportformationofnew
healthy bone mass. Several new therapeutical procedures are
under investigation.
Acknowledgments
The paper was supported by the Grant Agency of Charles
University in Prague Grant GAUK 84208, and by the
Ministry of Health Research Grant 000 237280.
DisclosurePolicy
The authors declare no conﬂict of interests.
References
[1] P. Hanova, K. Pavelka, C. Dosta, I. Holcatova, and H. Pikhart,
“Epidemiology of rheumatoid arthritis, juvenile idiopathic
arthritis and gout in two regions of the Czech Republic in
a descriptive population-based survey in 2002-2003,” Clinical
and Experimental Rheumatology, vol. 24, no. 5, pp. 499–507,
2006.
[2] D.Simon,C.Fernando,P.Czernichow,andA.M.Prieur,“Lin-
ear growth and ﬁnal height in patients with systemic juvenile
idiopathic arthritis treated with longterm glucocorticoids,”
Journal of Rheumatology, vol. 29, no. 6, pp. 1296–1300, 2002.
[ 3 ] S .J .W a n g ,Y .H .Y a n g ,Y .T .L i n ,C .M .Y a n g ,a n dB .L .C h i a n g ,
“Attained adult height in juvenile rheumatoid arthritis with or
without corticosteroid treatment,” Clinical Rheumatology,v o l .
21, no. 5, pp. 363–368, 2002.
[ 4 ]P .H .P e p m u e l l e r ,J .T .C a s s i d y ,S .H .A l l e n ,a n dL .S .
Hillman, “Bone mineralizationand bone mineral metabolism
in children with juvenile rheumatoid arthritis,” Arthritis &
Rheumatism, vol. 39, no. 5, pp. 746–757, 1996.
[ 5 ]C .J .H e n d e r s o n ,B .L .S p e c k e r ,R .I .S i e r r a ,B .N .C a m p a i g n e ,
and D. J. Lovell, “Total-body bone mineral content in
non-corticosteroid-treated postpubertal females with juvenile
rheumatoid arthritis: frequency of osteopenia and contribut-
ing factors,” Arthritis & Rheumatism, vol. 43, no. 3, pp. 531–
540, 2000.
[6] A. M. Reed, M. Haugen, L. M. Pachman, and C. B. Langman,
“Repair of osteopenia in children with juvenile rheumatoid
arthritis,” Journal of Pediatrics, vol. 122, no. 5, pp. 693–696,
1993.
[ 7 ]J .R e e v e ,J .L o f t u s ,R .H e s p ,B .M .A n s e l l ,D .J .W r i g h t ,a n dP .
M.M.Woo,“Biochemicalprediction ofchangesinspinalbone
massinjuvenilechronic(orrheumatoid)arthritistreated with
glucocorticoids,” Journal of Rheumatology,v o l .2 0 ,n o .7 ,p p .
1189–1195, 1993.
[ 8 ]C .J .H e n d e r s o n ,G .D .C a w k w e l l ,B .L .S p e c k e re ta l . ,
“Predictors of total body bone mineral density in non-
corticosteroid- treated prepubertal children with juvenile
rheumatoid arthritis,” Arthritis & Rheumatism, vol. 40, no. 11,
pp. 1967–1975, 1997.
[9] G. Lien, B. Flatø, M. Haugen et al., “Frequency of osteopenia
in adolescents with early-onset juvenile idiopathic arthritis:
a long-term outcome study of one hundred ﬁve patients,”
Arthritis & Rheumatism, vol. 48, no. 8, pp. 2214–2223, 2003.
[10] M. Zak, C. Hassager, D. J. Lovell, S. Nielsen, C. J. Henderson,
and F. K. Pedersen, “Assessment of bone mineral density in
adults with a history of juvenile chronic arthritis: a cross-
sectional long-term followup study,” Arthritis & Rheumatism,
vol. 42, no. 4, pp. 790–798, 1999.
[11] M.Haugen,G.Lien,B.Flatø etal.,“Youngadultswith juvenile
arthritis in remission attain normal peak bone mass at the
lumbar spine and forearm,” Arthritis & Rheumatism, vol. 43,
no. 7, pp. 1504–1510, 2000.
[12] A. R. French, T. Mason, A. M. Nelson et al., “Osteopenia
in adults with a history of juvenile rheumatoid arthritis. A
population based study,” Journal of Rheumatology, vol. 29, no.
5, pp. 1065–1070, 2002.
[13] S. Varonos, B. M. Ansell, and J. Reeve, “Vertebral collapse in
juvenile chronic arthritis: its relationship with glucocorticoid
therapy,” Calciﬁed Tissue International, vol. 41, no. 2, pp. 75–
78, 1987.
[14] B. W. Badley and B. M. Ansell, “Fractures in still’s disease,”
Annals of the Rheumatic Diseases, vol. 19, pp. 135–142, 1960.Journal of Osteoporosis 5
[ 1 5 ]J .M .B u r n h a m ,J .S h u l t s ,R .W e i n s t e i n ,J .D .L e w i s ,a n dM .
B. Leonard, “Childhood onset arthritis is associated with an
increased risk of fracture: a population based study using the
General Practice Research Database,” Annals of the Rheumatic
Diseases, vol. 65, no. 8, pp. 1074–1079, 2006.
[16] U. Elsasser,B. Wilkins,R. Hesp, D. I. Thurnham, J.Reeve, and
B. M. Ansell, “Bone rarefaction and crush fractures in juvenile
chronic arthritis,” Archives of Disease in Childhood,v o l .5 7 ,n o .
5, pp. 377–380, 1982.
[17] K. Murray, R. J. Boyle, and L. P. Woo, “Pathological fractures
and osteoporosis in a cohort of 103 systemic onset juvenile
idiopathic arthritis patients,” Arthritis & Rheumatism, vol. 43,
supplement, p. S119, 2000.
[18] J. Roth, C. Palm, I. Scheunemann, M. B. Ranke, R. Schweizer,
and G. E. Dannecker, “Musculoskeletal abnormalities of the
forearm in patients with juvenile idiopathic arthritis relate
mainly to bone geometry,” Arthritis & Rheumatism,v o l .5 0 ,
no. 4, pp. 1277–1285, 2004.
[19] J. M. Burnham, J. Shults, H. Sembhi, B. S. Zemel, and M.
B. Leonard, “The dysfunctional muscle-bone unit in juvenile
idiopathicarthritis,”Journal of Musculoskeletal Neuronal Inter-
actions, vol. 6, no. 4, pp. 351–352, 2006.
[20] H. Lindehammar and B. Lindvall, “Muscle involvement in
juvenileidiopathicarthritis,”Rheumatology,vol.43,no.12,pp.
1546–1554, 2004.
[21] M. Gattorno, S. Vignola, F. Falcini et al., “Serum and synovial
ﬂuid concentrations of matrix metalloproteinases 3 and its
tissue inhibitor 1 in juvenile idiopathic arthritides,” Journal of
Rheumatology, vol. 29, no. 4, pp. 826–831, 2002.
[22] C.E.Rabinovich,“Bonemineralstatusinjuvenilerheumatoid
arthritis,” Journal of Rheumatology, vol. 27, no. 58, pp. 34–37,
2000.
[23] D.MaandG.Jones,“Television,computer,andvideoviewing;
physical activity; and upper limb fracture risk in children:
a population-based case control study,” Journal of Bone and
Mineral Research, vol. 18, no. 11, pp. 1970–1977, 2003.
[ 2 4 ]A .G o u l d i n g ,I .E .J o n e s ,R .W .T a y l o r ,S .M .W i l l i a m s ,a n d
P. J. Manning, “Bone mineral density and body composition
in boys with distal forearm fractures: a dual-energy x-ray
absorptiometrystudy,” Journal of Pediatrics, vol.139,no.4,pp.
509–515, 2001.
[25] E. M. O. Felin, S. Prahalad, E. W. Askew, and L. J. Moyer-
Mileur, “Musculoskeletal abnormalities of the tibia in juvenile
rheumatoid arthritis,” Arthritis & Rheumatism,v o l .5 6 ,n o .3 ,
pp. 984–994, 2007.
[ 2 6 ]V .E .M a c R a e ,C .F a r q u h a r s o n ,a n dS .F .A h m e d ,“ T h e
pathophysiology of the growth plate in juvenile idiopathic
arthritis,” Rheumatology, vol. 45, no. 1, pp. 11–19, 2006.
[27] M. T. Saha, J. Haapasaari, S. Hannula, S. Sarna, and H. L.
Lenko,“Growthhormoneiseﬀectiveinthetreatmentofsevere
growth retardation in children with juvenile chronic arthritis.
Double blind placebo-controlled followup study,” Journal of
Rheumatology, vol. 31, no. 7, pp. 1413–1417, 2004.
[ 2 8 ]L .H i l l m a n ,J .T .C a s s i d y ,L .J o h n s o n ,D .L e e ,a n dS .H .A l l e n ,
“Vitamin D metabolism and bone mineralization in children
with juvenile rheumatoid arthritis,” Journal of Pediatrics,v o l .
124, no. 6, pp. 910–916, 1994.
[29] A. G´ orska, M. Urban, M. Bartnicka, B. Zelazowska-
Rutkowska, and J. Wysocka, “Bone mineral metabolism in
children withjuvenileidiopathicarthritis,”OrtopediaTrauma-
tologia Rehabilitacja, vol. 10, no. 1, pp. 54–62, 2008.
[30] R. M. R. Pereira, V. Falco, J. E. Corrente, W. H. Chahade, and
N. H. Yoshinari, “Abnormalities in the biochemical markers
of bone turnover in children with juvenile chronic arthritis,”
Clinical and Experimental Rheumatology,v o l .1 7 ,n o .2 ,p p .
251–255, 1999.
[31] S. R. Goldring, “Pathogenesis of bone and cartilage destruc-
tion in rheumatoid arthritis,” Rheumatology, vol. 42, no. 2,
supplement, pp. ii11–ii16, 2003.
[32] V. Strand and A. F. Kavanaugh, “The role of interleukin-1 in
bone resorption in rheumatoid arthritis,” Rheumatology,v o l .
43, supplement 3, pp. iii10–iii16, 2004.
[33] K. Redlich, S. Hayer, A. Maieret al., “Tumor necrosis factor α-
mediated jointdestruction isinhibited by targeting osteoclasts
with osteoprotegerin,” Arthritis & Rheumatism, vol. 46, no. 3,
pp. 785–792, 2002.
[34] A. Viswanathanand F.A. Sylvester, “Chronicpediatric inﬂam-
matory diseases: eﬀects on bone,” Reviews in Endocrine and
Metabolic Disorders, vol. 9, no. 2, pp. 107–122, 2008.
[35] S. Wei, H. Kitaura, P. Zhou, F. Patrick Ross, and S. L.
Teitelbaum, “IL-1 mediates TNF-induced osteoclastogenesis,”
Journal of Clinical Investigation, vol. 115, no. 2, pp. 282–290,
2005.
[36] B. M. Thomson, G. R. Mundy, and T. J. Chambers, “Tumor
necrosis factors α and β induce osteoblastic cells to stimulate
osteoclasticboneresorption,” Journal of Immunology,vol.138,
no. 3, pp. 775–779, 1987.
[37] W. Vanden Berghe, L. Vermeulen, P. Delerive, K. De Bosscher,
B. Staels, and G. Haegeman, “A paradigm for gene regulation:
inﬂammation, NF-κBa n dP P A R , ”Advances in Experimental
Medicine and Biology, vol. 544, pp. 181–196, 2003.
[38] M. S. Nanes,“Tumor necrosis factor-α: molecular and cellular
mechanisms in skeletal pathology,” Gene,vol. 321, no. 1-2, pp.
1–15, 2003.
[39] B.J.Smith,M.R.Lerner,S.Y.Buetal.,“Systemicbonelossand
induction of coronary vessel disease in a rat model of chronic
inﬂammation,”Bone, vol. 38, no. 3, pp. 378–386, 2006.
[ 4 0 ]K .T .S t e e v e ,P .M a r c ,T .S a n d r i n e ,H .D o m i n i q u e ,a n d
F. Yannick, “IL-6, RANKL, TNF-alpha/IL-1: interrelations
in bone resorption pathophysiology,” Cytokine and Growth
Factor Reviews, vol. 15, no. 1, pp. 49–60, 2004.
[41] E. Jimi,I.Nakamura,L.T.Duong et al.,“Interleukin 1induces
multinucleation and bone-resorbing activity of osteoclasts in
the absence of osteoblasts/stromal cells,” Experimental Cell
Research, vol. 247, no. 1, pp. 84–93, 1999.
[42] I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of
rheumatoid arthritis,” Nature Reviews Immunology,v o l .7 ,n o .
6, pp. 429–442, 2007.
[43] C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harring-
ton, “IL-17 family cytokines and the expanding diversity of
eﬀector T cell lineages,”Annual Reviewof Immunology,v ol.25,
pp. 821–852, 2007.
[44] E. Lubberts, M. Koenders, and W. B. van den Berg, “The role
of T cell interleukin-17 in conducting destructive arthritis:
lessons from animal models,” Arthritis Research and Therapy,
vol. 7, no. 1, pp. 29–37, 2005.
[45] S. Kotake, N. Udagawa, N. Takahashi et al., “IL-17 in
synovial ﬂuids from patients with rheumatoid arthritis is a
potent stimulator of osteoclastogenesis,” Journal of Clinical
Investigation, vol. 103, no. 9, pp. 1345–1352, 1999.
[46] E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen et al.,
“IL-17 promotes bone erosion in murine collagen-induced
arthritis through loss of the receptor activator of NF-κB
ligand/osteoprotegerin balance,” Journal of Immunology,v o l .
170, no. 5, pp. 2655–2662, 2003.
[47] D. L. Lacey, E. Timms, H. L. Tan et al., “Osteoprotegerin
ligandisacytokinethatregulates osteoclastdiﬀerentiationand
activation,” Cell, vol. 93, no. 2, pp. 165–176, 1998.6 Journal of Osteoporosis
[48] H. Yasuda, N. Shima, N. Nakagawa et al., “Osteoclast diﬀer-
entiation factor is a ligand for osteoprotegerin/osteoclas-
togenesis-inhibitory factor and is identical to TRANCE/
RANKL,” Proceedings of the National Academy of Sciencesof the
United States of America, vol. 95, no. 7, pp. 3597–3602, 1998.
[49] J. M. W. Quinn, J. Elliott, M. T. Gillespie, and T. J.
Martin, “A combination of osteoclast diﬀerentiation factor
and macrophage- colony stimulating factor is suﬃcient for
both human and mouse osteoclast formation in vitro,”
Endocrinology, vol. 139, no. 10, pp. 4424–4427, 1998.
[50] K.Matsuzaki,N.Udagawa,N.Takahashietal.,“Osteoclastdif-
ferentiation factor (ODF) induces osteoclast-like cell forma-
tion in human peripheral blood mononuclear cell cultures,”
Biochemical and Biophysical Research Communications,v o l .
246, no. 1, pp. 199–204, 1998.
[51] W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., “Osteopro-
tegerin: a novel secreted protein involved in the regulation of
bone density,” Cell, vol. 89, no. 2, pp. 309–319, 1997.
[52] L. C. Hofbauer, S. Khosla, C. R. Dunstan, D. L. Lacey, W.
J. Boyle, and B. L. Riggs, “The roles of osteoprotegerin and
osteoprotegerin ligand in the paracrine regulation of bone
resorption,” Journal of Bone and Mineral Research,v o l .1 5 ,n o .
1, pp. 2–12, 2000.
[53] M. Ziolkowska, M. Kurowska, A. Radzikowska et al., “High
levels of osteoprotegerin and soluble receptor activator of
nuclearfactorkappaBligandinserum ofrheumatoidarthritis
patients and their normalization after anti-tumor necrosis
factor alpha treatment,” Arthritis & Rheumatism, vol. 46, no.
7, pp. 1744–1753, 2002.
[54] K. A. Rouster-Stevens, C. B. Langman, H. E. Price et al.,
“RANKL: osteoprotegerin ratio and bone mineral density in
children with untreated juvenile dermatomyositis,”Arthritis &
Rheumatism, vol. 56, no. 3, pp. 977–983, 2007.
[55] P. K. Sarma, R. Misra, and A. Aggarwal, “Elevated serum
receptor activator of NFκB ligand (RANKL), osteoprotegerin
(OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in
patients with juvenile idiopathic arthritis,” Clinical Rheuma-
tology, vol. 27, no. 3, pp. 289–294, 2008.
[ 5 6 ] P .S p e l l i n g ,E .B o n f a ,V .F .C a p a r b o ,a n dR .M .R .
Pereira, “Osteoprotegerin/RANKL system imbalance in active
polyarticular-onset juvenile idiopathic arthritis: a bone dam-
age biomarker?” Scandinavian Journal of Rheumatology,v o l .
37, no. 6, pp. 439–444, 2008.
[57] S. Agarwal, R. Misra, and A. Aggarwal, “Synovial ﬂuid
RANKL and matrix metalloproteinase levels in enthesitis
related arthritis subtype of juvenile idiopathic arthritis,”
Rheumatology International, vol. 29, no. 8, pp. 907–911, 2009.
[ 5 8 ]G .L i e n ,A .M .S e l v a a g ,B .F l a t øe ta l . ,“ At w o - y e a rp r o s p e c t i v e
controlled study of bone mass and bone turnover in children
with early juvenile idiopathic arthritis,” Arthritis & Rheuma-
tism, vol. 52, no. 3, pp. 833–840, 2005.
[59] F. Falcini, M. Ermini, and F. Bagnoli, “Bone turnover is
reduced in children with juvenile rheumatoid arthritis,”
Journal of Endocrinological Investigation, vol. 21, no. 1, pp. 31–
36, 1998.
[ 6 0 ]Y .L i ,A .L i ,K .S t r a i t ,H .Z h a n g ,M .S .N a n e s ,a n dM .N .
Weitzmann,“Endogenous TNFα lowers maximum peak bone
mass and inhibits osteoblastic smad activation through NF-
κB,” Journal of Bone and Mineral Research,v o l .2 2 ,n o .5 ,p p .
646–655, 2007.
[ 6 1 ]D .D i a r r a ,M .S t o l i n a ,K .P o l z e re ta l . ,“ D i c k k o p f - 1i sam a s t e r
regulator of joint remodeling,” Nature Medicine,vol. 13, no. 2,
pp. 156–163, 2007.
[62] P.V.N.BodineandB.S.Komm,“Wntsignalingandosteoblas-
togenesis,” Reviews in Endocrine and Metabolic Disorders,v o l .
7, no. 1-2, pp. 33–39, 2006.
[63] V. Krishnan, H. U. Bryant, and O. A. MacDougald, “Reg-
ulation of bone mass by Wnt signaling,” Journal of Clinical
Investigation, vol. 116, no. 5, pp. 1202–1209, 2006.
[64] D. A. Glass 2nd, P. Bialek, J. D. Ahn et al., “Canonical
Wnt signaling in diﬀerentiated osteoblasts controls osteoclast
diﬀerentiation,” Developmental Cell, vol.8, no.5, pp. 751–764,
2005.
[65] R. Lamb, W. Thomson, E. Ogilvie, and R. Donn, “Wnt-1-
inducible signaling pathway protein 3 and susceptibility to
juvenile idiopathic arthritis,” Arthritis & Rheumatism, vol. 52,
no. 11, pp. 3548–3553, 2005.
[66] K. E. Sullivan, “Inﬂammation in juvenile idiopathic arthritis,”
Pediatric Clinics of North America, vol. 52, no. 2, pp. 335–357,
2005.
[ 6 7 ]N .J .P e a k e ,H .E .F o s t e r ,K .K h a w a j a ,T .E .C a w s t o n ,a n dA .D .
Rowan, “Assessment of the clinical signiﬁcance of gelatinase
activity in patients with juvenile idiopathic arthritis using
quantitative protein substrate zymography,” Annals of the
Rheumatic Diseases, vol. 65, no. 4, pp. 501–507, 2006.
[68] N. J. Peake, K. Khawaja, A. Myers et al., “Levels of matrix
metalloproteinase (MMP)-1 in paired sera and synovial
ﬂuids of juvenile idiopathic arthritis patients: relationship
to inﬂammatory activity, MMP-3 and tissue inhibitor of
metalloproteinases-1 in a longitudinal study,” Rheumatology,
vol. 44, no. 11, pp. 1383–1389, 2005.
[69] M.L.Bianchi,“Glucorticoids andbone:somegeneralremarks
and some special observations in pediatric patients,” Calciﬁed
Tissue International, vol. 70, no. 5, pp. 384–390, 2002.
[70] E. Canalis, “Mechanisms of glucocorticoid action in bone,”
Current Osteoporosis Reports, vol. 3, no. 3, pp. 98–102, 2005.
[71] M. L. Blanchi, R. Cimaz, E. Galbiati, F. Corona, R. Cherubini,
and M. Bardare, “Bone mass change during methotrexate
treatment in patients with juvenile rheumatoid arthritis,”
Osteoporosis International, vol. 10, no. 1, pp. 20–25, 1999.
[72] K. Mandel, S. Atkinson, R. D. Barr, and P. Pencharz, “Skeletal
morbidity in childhood acute lymphoblastic leukemia,” Jour-
nal of Clinical Oncology, vol. 22, no. 7, pp. 1215–1221, 2004.
[ 7 3 ]A .B .C r a n n e y ,R .J .M c K e n d r y ,G .A .W e l l se ta l . ,“ T h e
eﬀect of low dose methotrexate on bone density,” Journal of
Rheumatology, vol. 28, no. 11, pp. 2395–2399, 2001.
[ 7 4 ]P .L a h d e n n e ,P .V ¨ ah¨ asalo, and V. Honkanen, “Inﬂiximab
or etanercept in the treatment of children with refractory
juvenile idiopathicarthritis: an open label study,” Annals of the
Rheumatic Diseases, vol. 62, no. 3, pp. 245–247, 2003.
[75] G. Simonini, T. Giani, S. Stagi, M. de Martino, and F. Falcini,
“Bone status over 1 yr of etanercept treatment in juvenile
idiopathicarthritis,”Rheumatology,vol.44,no.6,pp.777–780,
2005.
[76] P. F. Vojvodich, J. B. Hansen, U. Andersson, L. S¨ avendahl,
and S. Hagelberg, “Etanercept treatment improves longitudi-
nal growth in prepubertal children with juvenile idiopathic
arthritis,” Journal of Rheumatology, vol. 34, no. 12, pp. 2481–
2485, 2007.
[77] L. M. Ward, F. Rauch, and M. P. Whyte, “Alendronate for the
treatment of pediatric osteogenesis imperfecta: a randomized
placebo-controlled study,” Journal of Clinical Endocrinology &
Metabolism. In press.
[78] A.Reed, M.Haugen,L.M.Pachman,andC.B.Langman,“25-
Hydroxyvitamin D therapy in children with active juvenile
rheumatoid arthritis: short-term eﬀects on serum osteocalcinJournal of Osteoporosis 7
levelsandbonemineraldensity,”Journal of Pediatrics, vol.119,
no. 4, pp. 657–660, 1991.
[79] F. Falcini, S. Trapani, M. Ermini, and M. L. Brandi, “Intra-
venous administration of alendronate counteracts the in
vivo eﬀects of glucocorticoids on bone remodeling,” Calciﬁed
Tissue International, vol. 58, no. 3, pp. 166–169, 1996.
[80] A. Siamopoulou, A. Challa, P. Kapoglou, V. Cholevas, A. K.
Mavridis, and P. D. Lapatsanis, “Eﬀects of intranasal salmon
calcitonin in juvenile idiopathic arthritis: an observational
study,” Calciﬁed Tissue International, vol. 69, no. 1, pp. 25–30,
2001.
[81] D. Simon, A. M. Prieur, and P. Czernichow, “Treatment
of juvenile rheumatoid arthritis with growth hormone,”
HormoneResearch,vol.53,no.1,supplement,pp.82–86,2000.
[ 8 2 ]G .T o u a t i ,J .C .R u i z ,D .P o r q u e t ,C .K i n d e r m a n s ,A .M .
Prieur,andP.Czernichow,“Eﬀects onbonemetabolismofone
year recombinant human growth hormone administration to
children with juvenile chronic arthritis undergoing chronic
steroid therapy,” Journal of Rheumatology,v o l .2 7 ,n o .5 ,p p .
1287–1293, 2000.
[83] M. Rooney, U. M. Davies, J. Reeve, M. Preece, B. M. Ansell,
and P. M. M. Woo, “Bone mineral content and bone mineral
metabolism: changes after growth hormone treatment in
juvenile chronic arthritis,” Journal of Rheumatology,v o l .2 7 ,
no. 4, pp. 1073–1081, 2000.
[84] S. Bechtold, P. Ripperger, D. M¨ uhlbayer et al., “GH therapy
in juvenile chronic arthritis: results of a two-year controlled
study on growth and bone,” Journal of Clinical Endocrinology
and Metabolism, vol. 86, no. 12, pp. 5737–5744, 2001.
[85] R. M. Neer, C. D. Arnaud, J. R. Zanchetta et al., “Eﬀect of
parathyroid hormone (1-34) on fractures and bone mineral
density in postmenopausal women with osteoporosis,” The
New England Journal of Medicine, vol. 344, no. 19, pp. 1434–
1441, 2001.